Kessler Topaz is Proud to Recognize and Honor Women's History Month By Profiling Our Female Partners and Recognizing the Amazing Work They Do in Their Professional and Personal Lives
Margaret Mazzeo is a partner in the Firm’s Securities Department. Since joining the Firm in 2011 after completing her summer internship, Maggie has litigated both class and direct securities fraud actions on behalf of investors. She was a member of the trial team that secured a rare post-PSLRA plaintiff’s jury verdict in In re Longtop Financial Technologies Ltd. Securities Litigation, No. 11-cv-3658 (S.D.N.Y.). Maggie was also a member of the litigation team that achieved a $130 million recovery for plaintiffs in In re Allergan Generic Drug Pricing Securities Litigation (D.N.J.), a case arising out of the industrywide price-fixing scheme in the generic drug market, as well as the team that attained a $82.5 million recovery for Endo Pharmaceuticals shareholders in SEB Investment Management AB v. Endo International PLC, et al., No. 17-cv-3711 (E.D. Pa.), an action based on the company’s disclosures concerning the efficacy of its opioid drug, Opana ER. Maggie is currently representing shareholders in multiple high-profile securities fraud actions, including In re Celgene Securities Litigation (D.N.J.), which involves allegations pertaining to the company’s statements regarding two drugs in its new drug pipeline—Otezla and Ozanimod.
Maggie has co-authored articles on damages in securities fraud class actions published in the Securities Regulation Law Journal, the Review of Securities & Commodities Regulation, and the Rutgers University Law Review. She graduated magna cum laude from Franklin & Marshall College with a double major in Sociology and Spanish. Maggie received her law degree cum laude from the Temple University Beasley School of Law, where she was selected as a Beasley Scholar. Outside of work, Maggie enjoys traveling and spending time with her husband and two young children.